15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
16 citations
,
August 2002 in “Journal of Interferon and Cytokine Research” A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
June 2018 in “Reactions Weekly” A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
32 citations
,
July 2003 in “Annals of the Rheumatic Diseases” A 13-year-old girl with various symptoms was successfully treated for autoimmune disease using the antibiotic co-trimoxazole.
July 2024 in “Journal of Investigative Dermatology” January 2010 in “Chinese Medical Journal of Metallurgical Industry” Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
13 citations
,
March 2008 in “Journal of the European Academy of Dermatology and Venereology” Triamcinolone acetonide therapy for hair loss may cause a skin condition called linear lichen planus.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.